AZD4547

For research use only. Not for use in humans.

目录号：S2801 别名： ABSK 091

CAS No. 1035270-39-3

AZD4547 (ABSK 091)是一种新型选择性的FGFR抑制剂，靶向作用于FGFR1/2/3，在无细胞试验中IC50为0.2 nM/2.5 nM/1.8 nM，对FGFR4， VEGFR2(KDR)具有微弱的作用活性，对IGFR， CDK2和p38几乎没有作用活性。Phase 2/3。

规格

价格

库存

购买数量

10mM (1mL in DMSO)	RMB 1801.43	现货
5mg	RMB 901.31	现货
10mg	RMB 1395.39	现货
50mg	RMB 4661.52	现货
100mg	RMB 7125.05	现货
大包装	有超大折扣

大剂量询单有大折扣!

今日订购，明日送达，全国免运费！

全国免费电话：400-668-6834 | Email：info@selleck.cn

客户使用Selleck生产的AZD4547发表文献91篇：

Nature, 2021, 595(7869):730-734

PubMed: 34290403 ( click the link to review the publication )

Cancer Cell, 2019, 35(3):504-518

PubMed: 30827889 ( click the link to review the publication )

Nature, 2018, 553(7686):101-105

PubMed: 29258295 ( click the link to review the publication )

Science, 2017, 10.1126/science.aan4368

PubMed: 29191878 ( click the link to review the publication )

Nature, 2016, 30;534(7609):647-51.

PubMed: 27338794 ( click the link to review the publication )

Acta Neuropathol, 2021, 10.1007/s00401-021-02327-x

PubMed: 34046693 ( click the link to review the publication )

Sci Adv, 2021, 7(7)eabd2645

PubMed: 33579708 ( click the link to review the publication )

Clin Cancer Res, 2021, 27(9):2533-2548

PubMed: 33619172 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2021, 118(20)e2100342118

PubMed: 33975953 ( click the link to review the publication )

EMBO Mol Med, 2021, 13(9):e13193

PubMed: 34369083 ( click the link to review the publication )

Cancer Res, 2021, canres.2276.2020

PubMed: 33685992 ( click the link to review the publication )

Cancer Res, 2021, canres.4048.2020

PubMed: 34083250 ( click the link to review the publication )

Breast Cancer Res, 2021, 23(1):82

PubMed: 34344433 ( click the link to review the publication )

Cells, 2021, 10(6)1318

PubMed: 34070622 ( click the link to review the publication )

FASEB J, 2021, 35(2):e21286

PubMed: 33484478 ( click the link to review the publication )

J Transl Med, 2021, 19(1):401

PubMed: 34551773 ( click the link to review the publication )

Int J Oncol, 2021, 10.3892/ijo.2021.5167

PubMed: 33491755 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2020, 117(46):29025-29034

PubMed: 33144503 ( click the link to review the publication )

Genome Med, 2020, 18;12(1):17

PubMed: 32070411 ( click the link to review the publication )

EBioMedicine, 2020, 62:103131

PubMed: 33254023 ( click the link to review the publication )

Cancers (Basel), 2020, 12(9)E2697

PubMed: 32967224 ( click the link to review the publication )

Br J Cancer, 2020, 22

PubMed: 32439932 ( click the link to review the publication )

Br J Cancer, 2020, 10.1038/s41416-020-0952-1

PubMed: 32572172 ( click the link to review the publication )

Cell Oncol (Dordr), 2020, 10.1007/s13402-020-00562-0

PubMed: 33119860 ( click the link to review the publication )
Front Oncol, 2020, 10;10:331

PubMed: 32211337 ( click the link to review the publication )

Int J Mol Sci, 2020, 18;21(8):2825

PubMed: 32325639 ( click the link to review the publication )

Acta Pharmacol Sin, 2020, 10.1038/s41401-020-00567-3

PubMed: 33288861 ( click the link to review the publication )

Oncol Rep, 2020, 44(6):2581-2594

PubMed: 33125153 ( click the link to review the publication )

EMBO Mol Med, 2020, e11793

PubMed: 32720440 ( click the link to review the publication )

Biochem Genet, 2020, 10.1007/s10528-020-09982-x

PubMed: 32671511 ( click the link to review the publication )

BMC Pharmacol Toxicol, 2020, 21(1):61

PubMed: 32795383 ( click the link to review the publication )

Mol Cancer Res, 2020, 18(4):549-559

PubMed: 31941753 ( click the link to review the publication )

Stem Cell Res Ther, 2020, 11(1):67

PubMed: 32070424 ( click the link to review the publication )

Cancer Immunol Res, 2020, 8(12):1542-1553

PubMed: 33093218 ( click the link to review the publication )

Nat Commun, 2019, 10(1):2701

PubMed: 31221965 ( click the link to review the publication )

EMBO Mol Med, 2019, 11(2)

PubMed: 30610113 ( click the link to review the publication )

Cell Rep, 2019, 28(9):2331-2344

PubMed: 31461650 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):372

PubMed: 31438996 ( click the link to review the publication )

Aging (Albany NY), 2019, 11(18):7780-7795

PubMed: 31545294 ( click the link to review the publication )

Mol Cancer Res, 2019,

PubMed: 30257990 ( click the link to review the publication )

J Cell Mol Med, 2019, 23(4):2933-2942

PubMed: 30761743 ( click the link to review the publication )

J Cell Mol Med, 2019, 101111/jcmm14793

PubMed: 31692229 ( click the link to review the publication )

Sci Rep, 2019, 9(1):8726

PubMed: 31217507 ( click the link to review the publication )

Sci Rep, 2019, 9(1):1875

PubMed: 30755670 ( click the link to review the publication )

Sci Rep, 2019, 9(1):6004

PubMed: 30979919 ( click the link to review the publication )

Front Pharmacol, 2019,

PubMed: 31998131 ( click the link to review the publication )

Transl Oncol, 2019, 12(3):432-440

PubMed: 30562682 ( click the link to review the publication )

Reprod Sci, 2019, 26(7):979-987

PubMed: 30270745 ( click the link to review the publication )
Ocul Immunol Inflamm, 2019, 10.1080/09273948.2019.1672196

PubMed: 31657648 ( click the link to review the publication )

Oncol Lett, 2019, 18(6):6249-6260

PubMed: 31788102 ( click the link to review the publication )

Oncol Lett, 2019, 17(2):2303-2307

PubMed: 30719110 ( click the link to review the publication )

Hepatology, 2018, 10.1002/hep.30127

PubMed: 30067876 ( click the link to review the publication )

Cancer Lett, 2018, 427:38-48

PubMed: 29679612 ( click the link to review the publication )

Mol Cell Proteomics, 2018, 17(5):850-870

PubMed: 29371290 ( click the link to review the publication )

Oncogenesis, 2018, 7(9):71

PubMed: 30237393 ( click the link to review the publication )

Sci Rep, 2018, 8(1):12087

PubMed: 30108259 ( click the link to review the publication )

J Biol Chem, 2018, 293(38):14839-14849

PubMed: 30093411 ( click the link to review the publication )

J Proteomics, 2018, 170:130-140

PubMed: 28842319 ( click the link to review the publication )

Oncotarget, 2018, 9(100):37352-37366

PubMed: 30647837 ( click the link to review the publication )

Clin Cancer Res, 2017, 23(4):962-973

PubMed: 27535980 ( click the link to review the publication )

Clin Cancer Res, 2017, 15;23(18):5527-5536

PubMed: 28630215 ( click the link to review the publication )

Theranostics, 2017, 7(4):974-986

PubMed: 28382169 ( click the link to review the publication )

Oncogene, 2017, 10.1038/onc.2016.512

PubMed: 28263980 ( click the link to review the publication )

BMC Cancer, 2017, 17(1):191

PubMed: 28292264 ( click the link to review the publication )

PLoS One, 2017, 12(8):e0183181

PubMed: 28806774 ( click the link to review the publication )

J Med Invest, 2017, 64(3.4):262-265

PubMed: 28954993 ( click the link to review the publication )

Oncotarget, 2017,

PubMed: 29050315 ( click the link to review the publication )

Oncotarget, 2017, 8(6):10007-10024

PubMed: 28052020 ( click the link to review the publication )

Oncotarget, 2017, 8(70):115596-115608

PubMed: 29383184 ( click the link to review the publication )

Clin Cancer Res, 2016, 22(15):3884-93

PubMed: 26936917 ( click the link to review the publication )

Cancer Res, 2016, 76(11):3285-94

PubMed: 27197170 ( click the link to review the publication )

Int J Cancer, 2016,

PubMed: 26481559 ( click the link to review the publication )
Oncogene, 2016, 10.1038/onc.2016.216

PubMed: 27345413 ( click the link to review the publication )

J Neurosci, 2016, 36(16):4534-48

PubMed: 27098696 ( click the link to review the publication )

J Proteome Res, 2016, 15(12):4490-4504

PubMed: 27794612 ( click the link to review the publication )

Hum Mol Genet, 2016, 25(1):9-23

PubMed: 26494904 ( click the link to review the publication )

Oncotarget, 2016, 7(31-:50161-50179

PubMed: 27367030 ( click the link to review the publication )

Oncotarget, 2016, 7(18-:25983-6002

PubMed: 27036020 ( click the link to review the publication )

Nat Commun, 2015, 6:7002

PubMed: 25926053 ( click the link to review the publication )

Mol Cancer Ther, 2015, 14(10):2292-302

PubMed: 26294741 ( click the link to review the publication )

J Biol Chem, 2015, 290(44):26752-64

PubMed: 26370090 ( click the link to review the publication )

Scand J Rheumatol, 2015, 6:1-10

PubMed: 25743336 ( click the link to review the publication )

PLoS One, 2015, 10(6):e0123967

PubMed: 26053020 ( click the link to review the publication )

PLoS One, 2015, 10(4):e0124562

PubMed: 25893435 ( click the link to review the publication )

Pathol Oncol Res, 2015, 10.1007/s12253-015-9916-9

PubMed: 25749811 ( click the link to review the publication )

Tumour Biol, 2015, 10.1007/s13277-015-3237-1

PubMed: 25691251 ( click the link to review the publication )

Oncotarget, 2015,

PubMed: 25576915 ( click the link to review the publication )

Cell Physiol Biochem, 2014, 33(3):633-45

PubMed: 24642893 ( click the link to review the publication )

Gastric Cancer, 2014, 10.1007/s10120-014-0444-1

PubMed: 25407459 ( click the link to review the publication )

Mol Cell Biol, 2014, 34(18):3535-45

PubMed: 25022753 ( click the link to review the publication )

Celon Pharma Inc, 2013, Paulina Grygielewicz

PubMed: ( click the link to review the publication )

产品安全说明书

FGFR抑制剂选择性比较

生物活性

产品描述

特性

AZD4547高选择性作用于 FGFR1-3，比作用于FGFR4选择性高。AZD4547有效作用于野生型和突变型FGFR酪氨酸激酶活性。

靶点

FGFR1 ^[1] (Cell-free assay)	FGFR3 ^[1] (Cell-free assay)	FGFR2 ^[1] (Cell-free assay)	KDR ^[1] (Cell-free assay)
0.2 nM	1.8 nM	2.5 nM	24 nM

体外研究

与 FGFR1-3相比, AZD4547作用于FGFR4，活性微弱，IC50为165 nM。AZD4547 只抑制重组 VEGFR2 (KDR) 激酶活性， IC50为 24 nM,在体外选择性作用于一组多种代表性的人类激酶。0.1 μM AZD4547 作用于一系列重组激酶，包括 ALK, CHK1, EGFR, MAPK1, MEK1, p70S6K, PDGFR, PKB, Src, Tie2,和 PI3K，没有作用活性。相应地,在细胞磷酸化实验中，可观察到AZD4547 作用于FGFR1-3的选择性比作用于 FGFR4, IGFR, 和 KDR高。AZD4547在体外,只有作用于表达去调控FGFRs 如KG1a, Sum52-PE,和KMS11的肿瘤细胞，具有有效抗增殖活性，IC50 为18-281 nM,而对MCF7 及100 种以上其他肿瘤细胞无活性。AZD4547 处理人类肿瘤细胞，有效抑制FGFR 和 MAPK 磷酸化,这种作用存在剂量依赖性。AZD4547 也有效抑制FRS2 和 PLCγ磷酸化,及下游FGFR信号。另外, AZD4547作用于乳腺细胞系，MCF7和Sum52-PE 而不是KG1a和 KMS11细胞，影响AKT磷酸化。AZD4547处理Sum52-PE 和 KMS11细胞，显著诱导凋亡,作用于KG1a细胞，显著提高细胞周期在G1期停滞而不是凋亡, 而作用于MCF7细胞，对细胞周期分布和凋亡都没有作用效果。^[1]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Activity Description	PMID
SNU449	NIHp[5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		Mo\xO\|IhcA>?	NXrCe5pIUUN3ME2wMlA5OiEQvF2=	MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjN3MUOyNEc,OjZ\|NUGzNlA9N2F-
SK-HEP-1	NHHacFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NEX2SHI4OiCq	MVzJR\|UxRTBwMEi0JO69VQ>?	MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjN3MUOyNEc,OjZ\|NUGzNlA9N2F-
SNU475	NETZXoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NE\BVYs4OiCq	NG\zUGtKSzVyPUWuOEDPxE1?	NITVfFM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkO1NVMzOCd-Mk[zOVE{OjB:L3G+
Hep3B	NUjUSIVRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M1nNPFczKGh?	NGf0ToFKSzVyPU[uOFMh\|ryP	MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjN3MUOyNEc,OjZ\|NUGzNlA9N2F-
PLC/PRF5	NVvpbVd[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NWj0U3Q1PzJiaB?=	MlPiTWM2OD14LkW1JO69VQ>?	MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjN3MUOyNEc,OjZ\|NUGzNlA9N2F-
Hur7	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MoDQO\|IhcA>?	MVfJR\|UxRTdwMkWg{txO	MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjN3MUOyNEc,OjZ\|NUGzNlA9N2F-
HepG2	MlP3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MVK3NkBp	MoTqTWM2OD16LkezJO69VQ>?	NVHpRWx[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[zOVE{OjBpPkK2N\|UyOzJyPD;hQi=>
SNU449	MXrDcI9vd2enbnnjJIF{e2G7	NVjEXYMzOSEEtV2=	NVjXenN{OjRiaB?=	M3vBfIRm[3KnYYPld{Bkd2yxbomg[o9zdWG2aX;uJJNq\26rZnnjZY51dHl?	M4PQcFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4M{WxN\|IxLz5{NkO1NVMzODxxYU6=
SK-HEP-1	M4jwVWNtd26xZ3XubYMh[XO\|YYm=	NIjYdZIyKML3TR?=	MoXPNlQhcA>?	MXTk[YNz\WG\|ZYOgZ49td267IH\vdo1ifGmxbjDzbYdvcW[rY3HueIx6	NYLqb2dlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[zOVE{OjBpPkK2N\|UyOzJyPD;hQi=>
SNU449	NVLSd\|NVTnWwY4Tpc44hSXO\|YYm=	NUixZ\|kzOC1{IN88US=>	NEHuOlY1QCCq	MnK3Z4F2e2W\|IHGg[IVkemWjc3Wgc4YhTlKVMv-8kGFMXCxiYX7kJGVTUyCyaH;zdIhwenmuYYTpc44>	M3j0elxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4M{WxN\|IxLz5{NkO1NVMzODxxYU6=
SK-HEP-1	MWPGeY5kfGmxbjDBd5NigQ>?	M1jR[VAuOiEQvF2=	NFLJZlM1QCCq	M2XFW4NifXOnczDhJIRm[3KnYYPlJI9nKE[UU{NvwKxCU1RuIHHu[EBGWkticHjvd5Bpd3K7bHH0bY9v	M4SzVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4M{WxN\|IxLz5{NkO1NVMzODxxYU6=
BaF3 FLT3-TEL	M3XkUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NX[4NmtoT0l3ME20MlYhyrFiMD61O\|ch\|ryP	MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjJ7NEe0NUc,OjZ{OUS3OFE9N2F-
BaF3 RET-TEL	NV7xWWZ6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NXXUOpJST0l3ME2wMlM6KMLzIECuNFQ5KM7:TR?=	MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjJ7NEe0NUc,OjZ{OUS3OFE9N2F-
BaF3 Parental	NFexSldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M1XyNWdKPTExubWxNEDPxE1?	MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjJ7NEe0NUc,OjZ{OUS3OFE9N2F-
MOLM14 FLT3/ITD	NHOwWHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M2XyfWdKPTB;MD60PFQhyrFiMD6xOVch\|ryP	MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjJ7NEe0NUc,OjZ{OUS3OFE9N2F-
MV4-11 FLT3/ITD	MnryS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M3Ln[GdKPTB;MD60OVkhyrFiMD6wOFYh\|ryP	M2LQflxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4Mkm0O\|QyLz5{NkK5OFc1OTxxYU6=
TT RET C634W	NX\SenFvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M1jE[WdKPTB;Mj65JOKyKDBwOUC0JO69VQ>?	MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjJ7NEe0NUc,OjZ{OUS3OFE9N2F-
AN3-CA FGFR2 N550K, K310R	NUDOSI9iT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MonaS2k2OD1yLkCzNUDDuSByLkCyN{DPxE1?	MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjJ7NEe0NUc,OjZ{OUS3OFE9N2F-
MFE296 FGFR2 N550K	MmHsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NFfLR\|dIUTVyPUCuO\|MxKMLzIECuNFU4KM7:TR?=	Ml3sQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ{OUS3OFEoRjJ4Mkm0O\|QyRC:jPh?=
MFE280 FGFR2 S252W	NXvJR3c3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M4jMc2dKPTB;MD6yNVghyrFiMD6wO\|Mh\|ryP	M1;lRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4Mkm0O\|QyLz5{NkK5OFc1OTxxYU6=
Ishikawa FGFF2 over exp.	NYXYUohvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			Mki2S2k2OD12LkWgxtEhOS53MTFOwG0>	MnLlQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ{OUS3OFEoRjJ4Mkm0O\|QyRC:jPh?=
HEC1A Normal FGFR2	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MkL3S2k2OO,7pUGwJO69VQ>?	NHvLTGM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkK5OFc1OSd-Mk[yPVQ4PDF:L3G+
A549	MUHD[YxtKH[rYXLpcIl1gSCDc4PhfS=>	MX:wMlEwOSEQvF2=	NG[yN4w1QCCq	M2W5WYVvcGGwY3XzJGVzdG:2aX7pZkBqdmS3Y3XkJJZq[WKrbHn0fUBtd3O\|	NXnXTGhJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[wOVMxOjBpPkK2NFU{ODJyPD;hQi=>
SGC-7901	NEPGVJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF\KXYgyKG6PLUGwJO69VQ>?	NUn5OHlWPzJiaB?=	MVfJR\|UxKG:oIEWtNVAh\|ryPLDDpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCmb4PlJIRmeGWwZHXueIx6	NHnpTJc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUW3OlkyPSd-MkW1O\|Y6OTV:L3G+
HGC-27	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYq0fXB1OSCwTT2xNEDPxE1?	NUGxVVE6PzJiaB?=	NIr3WndKSzVyIH;mJFUuOTBizszNMEBqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDkc5NmKGSncHXu[IVvfGy7	M2HGZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NUe2PVE2Lz5{NUW3OlkyPTxxYU6=
MKN-28	MoXwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFHSZVEyKG6PLUGwJO69VQ>?	M2W0OFczKGh?	MkHXTWM2OCCxZjC1MVExKM7:TTygbY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliZH;z[UBl\XCnbnTlcpRtgQ>?	NXjy[YFkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW1O\|Y6OTVpPkK1OVc3QTF3PD;hQi=>
NCI-N87	M{GxVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEXLbHEyKG6PLUGwJO69VQ>?	NIL0O204OiCq	MYfJR\|UxKG:oIEWtNVAh\|ryPLDDpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCmb4PlJIRmeGWwZHXueIx6	M4frN\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NUe2PVE2Lz5{NUW3OlkyPTxxYU6=
KATOIII	Mof4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MV:xJI5ONTFyIN88US=>	M{m1SFczKGh?	MUDJR\|UxKG:oIEGwMVExOCCwTTygbY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliZH;z[UBl\XCnbnTlcpRtgQ>?	MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTV5NkmxOUc,OjV3N{[5NVU9N2F-
SNU-16	Mof5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGTKbpQyKG6PLUGwJO69VQ>?	M1HWfFczKGh?	MYHJR\|UxKG:oIEGwMVExOCCwTTygbY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliZH;z[UBl\XCnbnTlcpRtgQ>?	M4\xRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NUe2PVE2Lz5{NUW3OlkyPTxxYU6=
4T1	NUntUHVvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MXvJR\|UxRTBwNkVCtVAvOTFizszN	MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDZ2Mki5N{c,OjR4NEK4PVM9N2F-
MDA-MB-468	NVS4bnB6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MYrJR\|UxRTRwOdMxNE45PSEQvF2=	MkDVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR4NEK4PVMoRjJ2NkSyPFk{RC:jPh?=
HCT116	NXPndVFqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MlLBTWM2OD1zNT65xtEyNjh{IN88US=>	NVLJWoFERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS2OFI5QTNpPkK0OlQzQDl\|PD;hQi=>
SW620	MnPFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MlOzTWM2OO,:nkKwJO69VQ>?	NYrTWG1XRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS2OFI5QTNpPkK0OlQzQDl\|PD;hQi=>
MDA-MB-231	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MoL0TWM2OO,:nkKwJO69VQ>?	M3KyNFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NkSyPFk{Lz5{NE[0Nlg6OzxxYU6=
CT26	M3LsXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NXHEeXVjUUN3MP-8olIxKM7:TR?=	MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDZ2Mki5N{c,OjR4NEK4PVM9N2F-
SW480	NH[zeGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MV;JR\|Ux97zgMkCg{txO	NELoWZQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NE[0Nlg6Oyd-MkS2OFI5QTN:L3G+
4T1	M2S2XmFxd3C2b4Ppd{BCe3OjeR?=	MlPzNU4zPS1{MDFOwG0>	MWGyOEBp	NUj0NXZmcW6mdXPld{BieG:ydH;zbZMh\G:\|ZTDk[ZBmdmSnboTsfS=>	MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDZ2Mki5N{c,OjR4NEK4PVM9N2F-
KG1a	M3q5d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MVTJR\|UxRTBwMEG4JO69VQ>?	NXnWcVBkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKzOlk6OjhpPkKyN\|Y6QTJ6PD;hQi=>
Sum52-PE	NV3YfVQ6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MU\JR\|UxRTBwMESxJO69VQ>?	Mn;rQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ\|Nkm5NlgoRjJ{M{[5PVI5RC:jPh?=
KMS11	M17vcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NWXJOIVUUUN3ME2wMlI5OSEQvF2=	NUfVWGdMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKzOlk6OjhpPkKyN\|Y6QTJ6PD;hQi=>
MCF7	NEX2TIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NXy3R4dxUUN3ME6zNEDPxE1?	M133ZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{M{[5PVI5Lz5{MkO2PVkzQDxxYU6=
KG1	MWXGeY5kfGmxbjDhd5NigQ>?		MVi3NkBpenN?	NX3MTFNNUW6qaXLpeIlwdiCxZjDGS2ZTOSCrbjDoeY1idiCNR{GgZ4VtdHNiYYPz[ZN{\WRiYYOgd5VxeHKnc4Ppc44hd2ZiY3XscEBxem:uaX\ldoF1cW:wIHHmeIVzKDd{IHjyd{BjgSCVUlKvR2NMNThiYYPzZZktKEmFNUCgQUAxNjByMEKg{txONg>?	M1v1OFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5MUG3OFI4Lz5{N{GxO\|QzPzxxYU6=
RT112	MVHGeY5kfGmxbjDhd5NigQ>?		MV23NkBpenN?	MUnJcohq[mm2aX;uJI9nKE[JRmKzJIlvKGi3bXHuJHJVOTF{IHPlcIx{KGG\|c3Xzd4VlKGG\|IIP1dJBz\XO\|aX;uJI9nKGOnbHygdJJwdGmoZYLheIlwdiCjZoTldkA4OiCqcoOgZpkhW1KEL1PDT{05KGG\|c3H5MEBKSzVyIE2gNE4xODB4IN88UU4>	M3PyV\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5MUG3OFI4Lz5{N{GxO\|QzPzxxYU6=
KG1	MXPBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		NFn5emU4OiCqcoO=	NULuflAzSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDLS\|Eh[2WubIOg[ZhxemW\|c3nu[{BHT0[UMTDh[pRmeiB5MjDodpMtKEmFNUCgQUAxNjByMUmg{txONg>?	Mn:5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl5N{W5N\|coRjJ7N{e1PVM4RC:jPh?=
KG1	NXr6e245SW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		Mn[5O\|IhcHK\|	NVjzc3VXSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDLS\|Eh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IFPDT{05KGG\|c3H5MEBKSzVyIE2gNE4xODN\|IN88UU4>	MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDZ6N{KwOEc,Ojh4OEeyNFQ9N2F-
SNU16	MXnBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		NV\Fe\|lwPzJiaILz	NV7QTmF{SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDTUnUyPiClZXzsd{Bi\nSncjC3NkBpenNiYomgR2NMNThiYYPzZZktKEmFNUCgQUAxNjByM{Sg{txONg>?	MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDZ6N{KwOEc,Ojh4OEeyNFQ9N2F-
SNU16	MUHGeY5kfGmxbjDhd5NigQ>?		MnXFO\|IhcHK\|	MmHzTY5pcWKrdHnvckBw\iC{ZXPvcYJqdmGwdDDGS2ZTOiCrbjDoeY1idiCVTmWxOkBk\WyuczDhd5Nme3OnZDDhd{B{fXCycnXzd4lwdiCxZjDj[YxtKHC{b3zp[oVz[XSrb36gZYZ1\XJiN{KgbJJ{KGK7IGPSRk9ES0tvODDhd5NigSxiSVO1NEA:KDBwMECzOkDPxE1w	MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzFzN{SyO{c,OjdzMUe0Nlc9N2F-
SNU16	NETPOXJCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		M13KR\|czKGi{cx?=	MmT1RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCVTmWxOkBk\WyuczDlfJBz\XO\|aX7nJGZITlJ{IHHmeIVzKDd{IHjyd{whUUN3MDC9JFAvODB4MjFOwG0v	NHzXc3Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUe3OVk{Pyd-Mkm3O\|U6Ozd:L3G+
KG1	MX\BcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		NW\DWIRqPzJiaILz	M3fQVmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgSmdHWjFvdILhcpNtd2OjdHXkJIh2dWGwIFvHNUBk\WyuczDh[pRmeiB5MjDodpMh[nliQ1PLPE9OXFRiYYPzZZktKEmFNUCgQUAxNjByNkSg{txONg>?	Mo\aQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd\|NEi1N\|coRjJ5M{S4OVM4RC:jPh?=
SNU16	NFnwTmRCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		NGrNPHQ4OiCqcoO=	M4nWOGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgSmdHWjJvYX3wcIlncWWmIHj1cYFvKFOQVUG2JINmdGy\|IHHmeIVzKDd{IHjyd{BjgSCFQ1u4M21VXCCjc4PhfUwhUUN3MDC9JFAvODF\|NDFOwG0v	NYe1O2k{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkezOFg2OzdpPkK3N\|Q5PTN5PD;hQi=>
KATO III	MnjUSpVv[3Srb36gZZN{[Xl?		M2rvVlczKGi{cx?=	NFLyVFZKdmirYnn0bY9vKG:oIF\HSnIzKGmwIHj1cYFvKEuDVF:gTWlKKGOnbHzzJIF{e2W\|c3XkJIF{KGmwaHnibZRqd25ib3[gZ4VtdCCycn;sbYZmemG2aX;uJIFnfGW{IEeyJIhzeyCkeTDj[YxtKGOxdX70bY5oKGurdD24JIF{e2G7LDDJR\|UxKD1iMD6wNVQyKM7:TT6=	M3vWWlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6N{G0OlkzLz5{OEexOFY6OjxxYU6=
KG1	NUTlWHEyTnWwY4Tpc44h[XO\|YYm=		MX23NkBpenN?	MnznTY5pcWKrdHnvckBw\iCIR1\SNW9ROiCodYPl[EBHT0[UMTDpckBpfW2jbjDLS\|Eh[2WubIOgZZN{\XO\|ZXSgZZMhcW6qaXLpeIlwdiCxZjDj[YxtKHC{b3zp[oVz[XSrb36gZYZ1\XJiN{KgbJJ{KGK7IHPlcIwh[2:3boTpcochc2m2LUigZZN{[XluIFnDOVAhRSByLkCxOlEh\|ryPLh?=	MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDdzNE[5Nkc,Ojh5MUS2PVI9N2F-
KATO III	NVvKNHRoTnWwY4Tpc44h[XO\|YYm=		Mo[zO\|IhcHK\|	MU\Jcohq[mm2aX;uJI9nKE[JRmKyJIlvKGi3bXHuJGtCXE9iSVnJJINmdGy\|IHHzd4V{e2WmIHHzJJN2eHC{ZYPzbY9vKG:oIHPlcIwheHKxbHnm[ZJifGmxbjDh[pRmeiB5MjDodpMh[nliU2LCM2NEUy16IHHzd4F6NCCLQ{WwJF0hOC5yMkCyJO69VS5?	NG\xcIo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{GxO\|QzPyd-MkexNVc1Ojd:L3G+
SNU16	M3H4N2Z2dmO2aX;uJIF{e2G7		NHnUeJg4OiCqcoO=	MlLmTY5pcWKrdHnvckBw\iCIR1\SNkBqdiCqdX3hckBUVlVzNjDj[YxteyCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKGOnbHygdJJwdGmoZYLheIlwdiCjZoTldkA4OiCqcoOgZpkh[2WubDDjc5VvfGmwZzDrbZQuQCCjc4PhfUwhUUN3MDC9JFAvODJ3NDFOwG0v	NVfRbHJTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki3NVQ3QTJpPkK4O\|E1Pjl{PD;hQi=>
UM-UC-14	NE\pOJlCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		MUm3NkBpenN?	M2rzcWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iVV2tWWMuOTRiY3XscJMh\XiycnXzd4lv\yCIR1\SN{Bi\nSncjC3NkBpenNuIFnDOVAhRSByLkCyOlkh\|ryPLh?=	MkHlQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl5N{W5N\|coRjJ7N{e1PVM4RC:jPh?=
RT112	M4C2TWZ2dmO2aX;uJIF{e2G7		NWP3U25zPzJiaILz	MYLJcohq[mm2aX;uJI9nKE[JRmKzJIlvKGi3bXHuJHJVOTF{IHPlcIx{KGG\|c3Xzd4VlKGG\|IHnubIljcXSrb36gc4Yh[2WubDDwdo9tcW[ncnH0bY9vKGGodHXyJFczKGi{czDifUBk\WyuIHPveY51cW6pIHvpeE05KGG\|c3H5MEBKSzVyIE2gNE4xOjdizszNMi=>	NWLiUoxDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki3NVQ3QTJpPkK4O\|E1Pjl{PD;hQi=>
UM-UC-14	MV3GeY5kfGmxbjDhd5NigQ>?		NX;lfmZPPzJiaILz	MlL3TY5pcWKrdHnvckBw\iCIR1\SN{BufXSjboSgbY4hcHWvYX6gWW0uXUNvMUSgZ4VtdHNiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iClZXzsJJBzd2yrZnXyZZRqd25iYX\0[ZIhPzJiaILzJIJ6KGOnbHygZ492dnSrbnegb4l1NThiYYPzZZktKEmFNUCgQUAxNjB{N{Gg{txONg>?	MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDdzNE[5Nkc,Ojh5MUS2PVI9N2F-
RT112	M2XzNWFvfGmycn;sbYZmemG2aY\lJIF{e2G7		M2[xZlczKGi{cx?=	MVPBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKFKWMUGyJINmdGy\|IHHmeIVzKDd{IHjyd{BjgSCPVGSgZZN{[XluIFfJOVAhRSByLkCyPVIh\|ryPLh?=	NVfSfolyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke1PVk4PDJpPkK3OVk6PzR{PD;hQi=>
H1581	NGP6[4RHfW6ldHnvckBie3OjeR?=		NUnucYhUPzJiaILz	MVvJcohq[mm2aX;uJI9nKE[JRmKxJIlvKGi3bXHuJGgyPThzIHPlcIx{KGG\|c3Xzd4VlKGG\|IIP1dJBz\XO\|aX;uJI9nKGOnbHygdJJwdGmoZYLheIlwdiCjZoTldkA4OiCqcoOgZpkhW1KEL1PDT{05KGG\|c3H5MEBKSzVyIE2gNE4xOzJ7IN88UU4>	MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzFzN{SyO{c,OjdzMUe0Nlc9N2F-
NCI-H1581	NYTmRZhUSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		MVq3NkBpenN?	NU\wW3ZlSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDOR2kuUDF3OEGgZ4VtdHNiZYjwdoV{e2mwZzDGS2ZTOSCjZoTldkA4OiCqcoOsJGlEPTBiPTCwMlA1KM7:TT6=	MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTd5NUmzO{c,Ojl5N{W5N\|c9N2F-
B16F10	M2TQPWN6fG:2b4jpZ4l1gSCjc4PhfS=>		MoPPO\|IhcHK\|	MV;DfZRwfG:6aXPpeJkh[WejaX7zeEBud3W\|ZTDCNVZHOTBiY3XscJMh[W[2ZYKgO\|IhcHK\|IHL5JG1VXCCjc4PhfUwhUUN3MDC9JFAvODVzIN88UU4>	NHrPV2g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUezOlk6Oyd-MkW3N\|Y6QTN:L3G+
A549	NWj3fHd[S3m2b4TvfIlkcXS7IHHzd4F6		NIf5NoQ4OiCqcoO=	NUn4dFd4S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hSTV2OTDj[YxteyCjZoTldkA4OiCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwJF0hOC5yNkKg{txONg>?	NEf3eVE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUezOlk6Oyd-MkW3N\|Y6QTN:L3G+
NCI-H1581	M4\UWmZ2dmO2aX;uJIF{e2G7		NUHjO4RwPzJiaILz	M{fwcGlvcGmkaYTpc44hd2ZiRlfGVlEhcW5iaIXtZY4hVkOLLVixOVgyKGOnbHzzJIF{e2W\|c3XkJIF{KGmwaHnibZRqd25ib3[gZ4VtdCCycn;sbYZmemG2aX;uJIFnfGW{IEeyJIhzeyCkeTDj[YxtKGOxdX70bY5oKGurdD24JIF{e2G7LDDJR\|UxKD1iMD6wOlI3KM7:TT6=	MoDzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh5MUS2PVIoRjJ6N{G0OlkzRC:jPh?=
RT112	MlLMRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		NF6ycpk4OiCqcoO=	MoT4RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCUVEGxNkBk\WyuczDlfJBz\XO\|aX7nJGZITlJ\|IHHmeIVzKDd{IHjyd{whUUN3MDC9JFAvODh\|ODFOwG0v	MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTd5NUmzO{c,Ojl5N{W5N\|c9N2F-
RT112	MUXBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		M3jDdVczKGi{cx?=	MkH6RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDGS2ZTOy2jbYDsbYZq\WRiaIXtZY4hWlRzMUKgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KEOFS{ivUXRVKGG\|c3H5MEBKSzVyIE2gNE4xQDh2IN88UU4>	M{f5RVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5M{S4OVM4Lz5{N{O0PFU{PzxxYU6=
NCI-H1581	MlewRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		NH;zU5M4OiCqcoO=	Mnv0RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDGS2ZTOS2jbYDsbYZq\WRiaIXtZY4hVkOLLVixOVgyKGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDDR2s5N02WVDDhd5NigSxiSVO1NEA:KDBwMEmyNUDPxE1w	NITFR3k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{O0PFU{Pyd-MkezOFg2Ozd:L3G+
HeLa 229	NXnhNo96S3m2b4TvfIlkcXS7IHHzd4F6		NIrvd5I4OiCqcoO=	NXjpd4tzS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUGWOYTCyNlkh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygTWM2OCB;IECuNVQh\|ryPLh?=	NVLmT\|BCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW3N\|Y6QTNpPkK1O\|M3QTl\|PD;hQi=>
BAF3	MXjBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		NH\rdVk4OiCqcoO=	NWXxXVU{SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBud3W\|ZTDCRWY{KGOnbHzzJIV5eHKnc4PpcochXkWJRmKyJIFnfGW{IEeyJIhzeyxiSVO1NEA:KDBwMkKyJO69VS5?	NH\xWnM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUe3OVk{Pyd-Mkm3O\|U6Ozd:L3G+
SGC7901	NXfBSHE{SW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		NVW3V2g5PzJiaILz	MXTBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKFOJQ{e5NFEh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygTWM2OCB;IEKuPEDPxE1w	M4fQOFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5OEK5OVE6Lz5{N{iyPVUyQTxxYU6=
MGC803	Mnn2RY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		MonzO\|IhcHK\|	NFnheoNCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3HR\|gxOyClZXzsd{Bi\nSncjC3NkBpenNiYomgUXRVKGG\|c3H5MEBKSzVyIE2gOk4zKM7:TT6=	MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzh{OUWxPUc,Ojd6Mkm1NVk9N2F-
BGC823	NHTFfJhCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		MoPqO\|IhcHK\|	NEH3S2tCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFLHR\|gzOyClZXzsd{Bi\nSncjC3NkBpenNiYomgUXRVKGG\|c3H5MEBKSzVyIE2gO{46KM7:TT6=	MlXmQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd6Mkm1NVkoRjJ5OEK5OVE6RC:jPh?=
HL7702	M3;wS2N6fG:2b4jpZ4l1gSCjc4PhfS=>		NImxNoQ4OiCqcoO=	NFu1UHBEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJVDd5MEKgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KE2WVDDhd5NigSxiSVO1NEA:KDF6LkKxJO69VS5?	NWXRfJF4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW3N\|Y6QTNpPkK1O\|M3QTl\|PD;hQi=>
U-2 OS	MYLxTHRUKHO\|YYm=			NX[wNGVneUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IGWtNkBQWyClZXzsdy=>	NIHmPVA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
A673	MkjJdWhVWyC\|c3H5			MUTxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhSTZ5MzDj[Yxtew>?	MoXRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
Saos-2	NFXwOnlyUFSVIIPzZZk>			NGHHfGpyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiU3Hvd{0zKGOnbHzz	NV\kUJAyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
BT-37	MVnxTHRUKHO\|YYm=			NWLybJZqeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IFLUMVM4KGOnbHzz	MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
RD	NIPGSmRyUFSVIIPzZZk>			MYPxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhWkRiY3XscJM>	NYHIWWJiRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
SK-N-SH	NHXxV41yUFSVIIPzZZk>			M1mwZpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCVSz3OMXNJKGOnbHzz	MojDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
BT-12	Mn[zdWhVWyC\|c3H5			NWLubIVEeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IFLUMVEzKGOnbHzz	MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
OHS-50	NGPFVoRyUFSVIIPzZZk>			Mn\LdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKE:KUz21NEBk\Wyucx?=	MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
fibroblast cells	NVLz[YtNeUiWUzDzd4F6			MYTxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5Ih[2:wdILvcEBJcCC5aXzkJJR6eGViZnnido9jdGG\|dDDj[Yxtew>?	MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
Rh41	M3vCSZFJXFNic4PhfS=>			NWnjUIFneUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IGLoOFEh[2WubIO=	MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
Rh30	NV;RNItGeUiWUzDzd4F6			M1G2[JFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCUaEOwJINmdGy\|	NGrndnQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
SJ-GBM2	NG\zeJlyUFSVIIPzZZk>			MorsdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKFOMLVfCUVIh[2WubIO=	MoLEQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
NB-EBc1	MlvFdWhVWyC\|c3H5			NH7sfGFyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiTlKtSWJkOSClZXzsdy=>	M3LkVFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
LAN-5	NVqxZZFneUiWUzDzd4F6			MUPxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhVEGQLUWgZ4VtdHN?	NUTmZZF[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
Rh18	NH\mPHhyUFSVIIPzZZk>			Mmm4dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKFKqMUigZ4VtdHN?	MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	p-FGFR / FGFR1 / p-AKT / AKT / p-ERK / ERK; PubMed: 28900173 Sci Rep Western blots (cropped) are shown for the indicated proteins in MDA-MB-361, BT474, and SKBR3 cells treated with AZD4547 (0, 1, 3, or 5 µM) for 72 hours. pFRS2; PubMed: 25576915 Oncotarget AZD4547 inhibits FGFR2 pathway activation in SNU16 and KATOIII cells. Cells were incubated with AZD4547 at the indicated doses. Cell lysates were immunoblotted for phospho-FGFR, phospho-FRS2, phospho- and total AKT, and phospho- and total ERK.	28900173 25576915
Growth inhibition assay	Cell viability; PubMed: 28900173 Sci Rep MDA-MB-361, BT474, and SKBR3 ErbB2-overexpressing breast cancer cells were treated with AZD4547 (0, 0.1, 0.3, 1, 3, or 5 µM) for 5 days. Then the viable fraction of each cell line was determined with an MTS assay. Cell viability; PubMed: 25576915 Oncotarget FGFR2-amplified GC cells are selectively sensitive to AZD4547. In vitro CCK-8 assay across a panel of 6 GC cells demonstrated that SNU16 and KATOIII cells were extremely sensitive to AZD4547 with IC50 values of 5-10 nM. Data (n = 6) are presented as mean ± SD.	28900173 25576915

体内研究

AZD4547按3 mg/kg剂量口服处理携带KMS11肿瘤的小鼠，每天两次，与空白对照组相比，显著抑制53%肿瘤生长，AZD4547 按 12.5 mg/kg剂量每天处理一次，或按 6.25 mg/kg剂量每天处理两次，则完全抑制肿瘤，这与p-FGFR3的药效学调节剂量正相关，且降低 KMS11肿瘤细胞增殖。而且, AZD4547按 12.5 mg/kg剂量口服处理给药FGFR1融合KG1a 移植瘤模型，每天一次，抑制65% 肿瘤生长。在有效剂量水平，AZD4547不表现出抗血管生成的效果。AZD4547 对血压没有显著作用效果，因此在体内缺乏抗-KDR 活性。相应地, AZD4547按6.25 mg/kg剂量口服处理对Cediranib敏感的移植瘤模型，包括 Calu-6, HCT-15 和 LoVo，每天两次，没有作用活性。^[1]

激酶实验：^[1]	- 合并 AZD4547 激酶活性: 使用浓度等于或低于相对K_m 的ATP，测定AZD4547抑制 FGFR1-3的人类重组激酶活性的效果。
细胞实验：^[1]	- 合并 Cell lines: KG1a, Sum52-PE, KMS11, 和MCF7 Concentrations: 溶于DMSO,终浓度为 ~1 μM Incubation Time: 72 小时 Method: 使用多种浓度AZD4547处理细胞72小时。通过 MTS 增殖实验获得抗增殖的IC50值。荧光激活细胞分选(FACS)中,细胞与70%乙醇混合，然后与碘化丙啶/RNase A标记溶液温育。使用 FACSCalibur 仪器和CellQuest分析软件测定细胞周期谱。为了分析凋亡，轻轻收集细胞和培养基，离心，然后冲洗细胞颗粒。细胞进行Annexin膜联蛋白 V-异硫氰酸荧光素(FITC)染色和碘化丙啶吸收。使用FACSCalibur仪器测定膜联蛋白 V染色阳性细胞比例，使用CellQuest分析软件进行象限分类。 (Only for Reference)
动物实验：^[1]	- 合并 Animal Models: 皮下注射LoVo, HCT-15, Calu-6, KMS11 或 KG1a的雌性Swiss衍生裸鼠和SCID小鼠 Dosages: 1.5-50 mg/kg Administration: 口服饲喂，每天一次或两次 (Only for Reference)

参考文献

[1] Gavine PR, et al. Cancer Res, 2012, 72(8), 2045-2056.

溶解度 (25°C)

体外	DMSO	92 mg/mL (198.45 mM)
	Water	Insoluble
	Ethanol	Insoluble
体内	从左到右依次将纯溶剂加入产品，现配现用(数据来自Selleck实验检测而非文献)： 4% DMSO+30% PEG 300+5% Tween 80+ddH2O	5mg/mL

* 溶解度检测是由Selleck技术部门检测的，可能会和文献中提供的溶解度有所差异，这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据 Download AZD4547 SDF

分子量	463.57
化学式	C₂₆H₃₃N₅O₃
CAS号	1035270-39-3
储存条件	3年-20°C 粉状 2年-80°C 溶于溶剂
别名	ABSK 091

动物体内配方计算器 (澄清溶液)

第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）

给药剂量

mg/kg

动物平均体重

每只动物给药体积

动物数量

只

第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系Selleck为您提供正确的澄清溶液配方）

% DMSO+ % + % Tween 80+ % ddH₂O

计算重置

计算结果:

工作液浓度： mg/ml；

DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，注：如该浓度超过该批次药物DMSO溶解度，请先联系Selleck）；

体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL ddH₂O，混匀澄清。

注意：1. 首先保证母液是澄清的；
2. 一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。

计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

质量

浓度

体积

分子量
=

×

×

*在配置溶液时，请务必参考Selleck产品标签上、SDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。

稀释计算器

用本工具协助配置特定浓度的溶液，使用的计算公式为：

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入输出 )

C1

V1

C2

V2
×

=

×

在配置溶液时，请务必参考Selleck产品标签上、SDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。.

连续稀释计算器方程

连续稀释
初始浓度:
稀释倍数:

计算结果

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

分子量计算器

通过输入化合物的化学式来计算其分子量：

注：化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量	浓度	体积	分子量
=	×	×
计算

临床试验信息 (data from https://clinicaltrials.gov, updated on 2021-09-06)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT02824133	Completed	Drug: AZD4547	Recurrent IDHwt Gliomas With FGFR3-TACC3 Fusion\|Recurrent IDHwt Gliomas With FGFR1-TACC1 Fusion	Assistance Publique - Hôpitaux de Paris	September 2015	Phase 1\|Phase 2
NCT01824901	Completed	Drug: docetaxel\|Drug: AZD4547	Recurrent Non-small Cell Lung Cancer\|Squamous Cell Lung Cancer	ECOG-ACRIN Cancer Research Group\|National Cancer Institute (NCI)\|Eastern Cooperative Oncology Group	September 2013	Phase 1\|Phase 2
NCT01795768	Unknown status	Drug: AZD 4547	Gastric Cancer\|Oesophageal Cancer\|Breast Cancer\|Squamous Cell Carcinoma of the Lung	Royal Marsden NHS Foundation Trust\|AstraZeneca	September 2012	Phase 2
NCT01791985	Completed	Drug: AZD4547 / anastrozole or letrozole	Breast Cancer	Imperial College London\|Cancer Research UK\|AstraZeneca	July 2012	Phase 1\|Phase 2
NCT01213160	Completed	Drug: AZD4547	Cancer\|Advanced Solid Malignancies	AstraZeneca	November 2010	Phase 1

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

FGFR Signaling Pathway Map

FGFR Inhibitors with Unique Features

选择性强的FGFR抑制剂

PD173074 : FGFR1-selective, IC50=~25 nM.
FDA批准的FGFR抑制剂

Ponatinib (AP24534) : Approved by FDA for resistant or intolerant CML and Ph+ ALL.
最新的FGFR抑制剂

SSR128129E ^New : Orally-active and allosteric FGFR1 inhibitor with IC50 of 1.9 μM, while not affecting other related RTKs.
经典的FGFR抑制剂

Dovitinib (TKI-258, CHIR-258) : Multitargeted RTK inhibitor for class III (FLT3/c-Kit), class IV (FGFR1/3) and class V (VEGFR1-4) RTKs.

研究领域

产品类型

定制您的化合物库

AZD4547

客户使用Selleck生产的AZD4547发表文献91篇：

产品安全说明书

FGFR抑制剂选择性比较

生物活性

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

参考文献

溶解度 (25°C)

化学数据 Download AZD4547 SDF

动物体内配方计算器 (澄清溶液)

计算器

摩尔浓度计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

稀释计算器

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

连续稀释计算器方程

连续稀释

计算结果

分子量计算器

总分子量：g/mol

摩尔浓度计算器

临床试验信息 (data from https://clinicaltrials.gov, updated on 2021-09-06)

技术支持

FGFR Signaling Pathway Map

FGFR Inhibitors with Unique Features

相关FGFR产品